{"entity":{"id":"nct01702155","kind":"trial","name":"Phase I/II Study of DFP-10917 in Patients With Acute Leukemia","aka":[],"tldr":"A phase 1/2 trial of DFP-10917 run by Delta-Fly Pharma, Inc., completed.","summary":"Phase I/II Study of DFP-10917 in Patients With Acute Leukemia is a phase 1/2 interventional study registered as NCT01702155 by Delta-Fly Pharma, Inc., with 69 participants enrolled, started 2012-10-10. Conditions recorded: Acute Myeloid Leukemia and Acute Lymphocytic Leukemia. Interventions recorded: DFP-10917.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT01702155","url":"https://clinicaltrials.gov/study/NCT01702155"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["dfp-10917"],"companies":["delta-fly-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01702155","phase":"1/2","setting":"A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia","sponsor":"Delta-Fly Pharma, Inc.","enrolled":69,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01702155/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"dfp-10917","kind":"drug","name":"DFP-10917","route":"/drugs/dfp-10917/"}],"company":[{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","route":"/companies/delta-fly-pharma/"}]}}